Results 81 to 90 of about 16,063 (220)
Molecular Brain, 2019 Aim The amyloid precursor protein (APP) is endoproteolytically processed to generate either the neurotoxic beta-amyloid peptide (Aβ) or the secreted ectodomain APP alpha (sAPPα).
Christian Tackenberg, Roger M. Nitsch
doaj +1 more source
Advanced Science, Volume 13, Issue 21, 13 April 2026.Polycarbonate nanogels enable lipid‐free delivery of anti‐MFAP‐5 siRNA into cancer‐associated fibroblasts (CAF) in hepatocellular carcinoma. In a cirrhotic murine model, this approach silences MFAP‐5, reduces fibroblast activation, and suppresses tumor growth by inhibiting NOTCH/Hes1‐driven angiogenesis. CAF‐targeted MFAP‐5 RNAi and conserved signaling
Paul Schneider +20 more
wiley +1 more source
Role of membrane biophysics in Alzheimer\u27s–related cell pathways [PDF]
, 2015 Cellular membrane alterations are commonly observed in many diseases, including Alzheimer's disease (AD). Membrane biophysical properties, such as membrane molecular order, membrane fluidity, organization of lipid rafts, and adhesion between membrane and
Bungart, Brittani L +4 more
core +8 more sources
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract INTRODUCTION Despite the identification of familial Alzheimer's disease (FAD) genes and neuropathological alterations, AD displays complex genetic heterogeneity and molecular pathogenesis that warrant further investigation. GBF1 (Golgi brefeldin A resistant guanine nucleotide exchange factor 1) regulates protein trafficking, and genetic ...
Sean J. Miller +16 more
wiley +1 more source
Group III Secretory Phospholipase A2 Enhances Alpha-Secretase-Dependent Amyloid Precursor Protein Processing Through Alterations in Membrane Fluidity [PDF]
Biophysical Journal, 2010 Phospholipases A2 (PLA2s) are responsible for maintenance of phospholipids homeostasis in cell membrane and implicated in neurodegenerative disease including Alzheimer's disease (AD). Among many types of secretory PLA2s, type III secretory PLA2 (sPLA2-III) is expressed in neuronal cells and contributes to cell differentiation and survival. Yet the role
Yang, Xiaoguang +3 more
openaire +1 more source
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract INTRODUCTION Alzheimer's Disease (AD) is a central nervous system (CNS) neurodegenerative disease leading to dementia, but can also show symptoms of motor deficits. It is not clear whether the peripheral motor deficits in AD are derived from upstream centers or intrinsic to the neuromuscular circuit.
Akhmetzada Kargazhanov +11 more
wiley +1 more source
alpha-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer's disease
, 2020 Background The disintegrin metalloproteinase 10 (ADAM10) is the main alpha-secretase acting in the non-amyloidogenic processing of APP. Some ADAM10 gene variants have been associated with higher susceptibility to develop late-onset AD, though clear clinical-genetic correlates remain elusive.
Agüero P +8 more
openaire +1 more source
Isoflavones and alzheimer’s disease: the effects of soy in diet [PDF]
, 2014 Pathologically, Alzheimer’s disease is a result of aggregation of amyloid peptides and protein tau in the brain forming neurofibrillary tangles which are highly toxic to neuronal circuits in the brain.
Habib, Sara +3 more
core +1 more source
Tetraspanin 3: A central endocytic membrane component regulating the expression of ADAM10, presenilin and the amyloid precursor protein [PDF]
, 2016 Despite existing knowledge about the role of the A Disintegrin and Metalloproteinase 10 (ADAM10) as the α-secretase involved in the non-amyloidogenic processing of the amyloid precursor protein (APP) and Notch signalling we have only limited information ...
Altmeppen, Hermann +10 more
core +1 more source
A perspective: PLA2G4A as drug target for vascular inflammation in Alzheimer's disease
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract Anti‐amyloid therapies for Alzheimer's disease (AD) modestly slow cognitive decline but carry significant risk of amyloid‐related imaging abnormalities (ARIAs), brain swelling, and hemorrhage, particularly in apolipoprotein E ε4 carriers. Cerebral amyloid angiopathy (CAA) and vascular inflammation drive this vulnerability, highlighting the ...
Ambreen Kanwal +12 more
wiley +1 more source